Other potential markers include the Prostate Health Index (PHI, which combines total and free PSA and [−2]proPSA); or Stockholm 3 test (S3M, which combines five proteins; total and free PSA; kallikrein 2; MSMB and MIC1, in combination with a panel of 254 CaP-related SNPs, and demographic and clinical data including familial history and previous prostate biopsies), which have a higher specificity than PSA and are associated with higher tumor aggressiveness, thereby reducing overdiagnosis [19]. Here, KLK3 is linked to neoplasm.